The CHS is a voluntary and measurable standard, which means its application can be objectively assessed. The CHS Verification Scheme allows organisations to measure the extent to which they have successfully applied the CHS requirements, and allows them, to demonstrate that they have done so. The Sc...heme offers four verification options; although each option is stand alone, the indicators used in the self-assessment are common to all options.
more
The escalating antimicrobial resistance (AMR) pandemic is a global public health threat with extensive health, economic and societal implications. Resistance emerges because of selection pressure from rational and indiscriminate antimicrobial use in human health as well as in the veterinary, agricul...ture and environmental sectors. Infections caused by resistant bacteria result in longer duration of illness, higher mortality rates and increased costs associated with alternative treatment. AMR further constrains procedures that rely on antimicrobial prophylaxis, and AMR is recognized as a threat to theworld economy.
Journal of Public Health | Vol. 39, No. 1, pp. 8–13 | doi:10.1093/pubmed/fdw015 | Advance Access Publication March 3 2016
more
Iran J Public Health, Vol. 45, No.11, Nov 2016, pp.1521-1522
Program Report for Collaborative Agreement: DFD-A-00-08-00309-00 September 30, 2008 -December 31, 2015
Saudi Journal of Biological Sciences. http://dx.doi.org/10.1016/j.sjbs.2016.03.006
Open Access
DHS Working Papers No. 127
DHS Working Papers No. 123
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand...ing access to affordable antiretroviral therapy (ART).
The report is supplemented by 11 drug profiles that contain more detailed information on pricing trends and patent barriers for key antiretroviral drugs and fixed-dose combinations. Also included is an annex of conditions that define eligibility for reduced prices from 15 pharmaceutical companies.
more